Transl Clin Pharmacol.  2014 Jun;22(1):13-18.

Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines

• Han S

Abstract

Primary health care providers play a critical role in maintaining public health, and the appropriate use of pharmaceutical products is one of the major parts of their practice. This series of articles, entitled 'Clinical Pharmacology Review for Primary Health Care Providers,' is intended to help primary health care providers select more appropriate prescriptions for frequently used drugs based on up-to-date information. We expect that this effort will contribute to improvements in public health and diminish unnecessary drug use.

MeSH Terms

Histamine Antagonists*
Pharmaceutical Preparations
Pharmacology
Pharmacology, Clinical*
Prescriptions
Primary Health Care*
Public Health
Histamine Antagonists
Pharmaceutical Preparations

Reference

References

1. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008; 1:145–155.

2. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011; 378:2112–2122.

3. Church MK, Maurer M. H(1)-antihistamines and urticaria: how can we predict the best drug for our patient? Clin Exp Allergy. 2012; 42:1423–1429.

4. De Sutter AI, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database Syst Rev. 2012; 2:CD004976. doi: 10.1002/14651858. CD004976.pub3.

5. Merrigan JM, Buysse DJ, Bird JC, Livingston EH. JAMA patient page. Insomnia. JAMA. 2013; 309:733.

6. Katelaris CH, Lee BW, Potter PC, Maspero JF, Cingi C, Lopatin A, et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy. 2012; 42:186–207. doi: 10.1111/j.1365-2222.2011.03891.x.

7. Baena-Cagnani CE, Badellino H. Pharmacotherapy of Allergic Diseases. In: WAO White Book on Allergy: Update 2013. World allergy organization. Milwaukee. 2013. 114–118.

8. Van Schoor J. Antihistamines: a brief review. Prof Nurs Today. 2012; 16:16–21.

9. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, antiinflammatory actions and cardiac effects. Clin Exp Allergy. 2002; 32:489–498.

10. Histamine antagonist. 2014. http://en.wikipedia.org/wiki/Pharmaceutical_drug/Accessed9May.

11. Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG. Pharmacokinetics of diphenhydramine in man. J Pharmacokinet Biopharm. 1975; 3:159–170.

12. Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. Eur J Clin Pharmacol. 1982; 22:359–365.

13. Simons KJ, Watson WT, Martin TJ, Chen XY, Simons FE. Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol. 1990; 30:665–671.

14. Thompson JA, Bloedow DC, Leffert FH. Pharmacokinetics of intravenous chlorpheniramine in children. J Pharm Sci. 1981; 70:1284–1286.

15. Simons FER, Simons KJ. Clinical pharmacology of H1-antihistamines. Simons FER, editor. Histamine and H1-antihistamines in allergic disease. 2nd ed. New York: Marcel Dekker;2002. p. 141–178.

16. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004; 351:2203–2217.

17. Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy. 1999; 29:S116–S124.

18. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007; 25:3837–3845.

19. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003; 35:99–106.

20. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008; 84:347–361. doi: 10.1038/sj.clpt.6100482.

21. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002; 113:S38–S46.

22. Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001; 107:751–762.

23. Gillard M, Christophe B, Wels B, Peck M, Massingham R, Chatelain P. H1 antagonists: receptor affinity versus selectivity. Inflamm Res. 2003; 52:S49–S50.

24. McDonald K, Trick L, Boyle J. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol. 2008; 23:555–70.

25. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012; 130:1049–62. doi: 10. 1016/j.jaci. 2012.07.053.

26. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebocontrolled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999; 104:927–933.

27. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000; 30:891–899.

28. Kaiser HB, Rooklin A, Spangler D, Capano D. Efficacy of loratadine compared with fexofenadine or placebo for the treatment of seasonal allergic rhinitis. Clin Drug Invest. 2001; 21:571–578.

29. Corren J, Harris AG, Aaronson D, Beaucher W, Berkowitz R, Bronsky E, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol. 1997; 100:781–788.

30. Kobza Black A, Greaves MW. Antihistamines in urticaria and angioedema. Simons FER, editor. Histamine and H1-antihistamines in allergic disease. 2nd ed. New York: Marcel Dekker;2002. p. 249–286.

31. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebocontrolled, parallel-group study. Br J Dermatol. 2003; 148:1212–1221.

32. Diepgen TL, Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multicountry, double-blind, randomized, placebocontrolled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002; 13:278–286.

33. De Sutter AI, Lemiengre M, Campbell H. Antihistamines for the common cold. Cochrane Database Syst Rev 2009. doi: 10.1002/14651858. CD001267.pub2.

34. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008; 4:487–504.

35. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol. 2000; 15:S3–S30.

36. Simons FER. H1-antihistamines in children. Simons FER, editor. Histamine and H1-antihistamines in allergic disease. 2nd Ed.New York: Marcel Dekker;2002. p. 437–64.

37. Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin. 2001; 17:241–255.

38. Meurer WJ, Potti TA, Kerber KA, Sasson C, Macy ML, West BT, et al. Potentially inappropriate medication utilization in the emergency department visits by older adults: analysis from a nationally representative sample. Acad Emerg Med. 2010; 17:231–237.

39. Park MJ, Shin JY, Kim HA, Park HJ, Kim MH, Shin SM, et al. Agreement of label information of antihistamine, antiallergy medications in pregnancy among Korea, the USA, the UK, and Japan. Kor J Clin Pharm. 2013; 23:327–333.